Financial Position - Mural Oncology reported cash and cash equivalents of $270.9 million as of December 31, 2023[4]. Research and Development - Research and development expenses for Q4 2023 were $42.2 million, primarily due to employee-related expenses and ARTISTRY-7[9]. - Enrollment is ongoing in ARTISTRY-6 and ARTISTRY-7, with ARTISTRY-7 evaluating nemvaleukin in 448 patients with platinum-resistant ovarian cancer[5]. - Mural Oncology plans to present preclinical data for IL-18 and IL-12 at the upcoming AACR conference and nominate development candidates later this year[5]. Operating Expenses - General and administrative expenses for Q4 2023 totaled $16.3 million, including $9.7 million in non-cash, share-based compensation[9]. - The company anticipates lower operating expenses in future quarters following the spin-out from Alkermes[9]. Financial Performance - The net loss for Q4 2023 was $59.5 million, which included $15.2 million in non-cash, share-based compensation[9]. - The company reiterates its cash runway projection into Q4 2025[2]. Future Outlook - The company expects to report top-line data results from cohort 2 of ARTISTRY-6 in the first half of 2025[5]. - Mural Oncology aims to explore partnerships to further investigate the potential of nemvaleukin and its preclinical programs[2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) (State or ...